TAVR术对比SAVR术治疗重度AS的住院费用分析——基于真实世界数据

孙辉, 侯士强, 金春林, 潘文志, 周达新, 王海银

中国医疗保险 ›› 2022, Vol. 0 ›› Issue (1) : 70-74.

中国医疗保险 ›› 2022, Vol. 0 ›› Issue (1) : 70-74. DOI: 10.19546/j.issn.1674-3830.2022.1.013
医药经济

TAVR术对比SAVR术治疗重度AS的住院费用分析——基于真实世界数据

  • 孙辉1,2, 侯士强3, 金春林1, 潘文志3, 周达新3, 王海银1
作者信息 +

In-hospital Costs Analysis of Transcatheter Versus Surgical Aortic Valve Replacement in the Treatment of Severe Aortic Stenosis——Based on Real World Data

  • Sun Hui1,2, Hou Shiqiang3, Jin Chunlin1, Pan Wenzhi3, Zhou Daxin3, Wang Haiyin1
Author information +
文章历史 +

摘要

目的:分析经导管主动脉瓣置换术(TAVR)对比外科主动脉瓣置换术(SAVR)治疗重度主动脉瓣狭窄(AS)的住院费用,为临床治疗决策与相关部门政策制定提供依据。方法:收集上海市某大型综合医院2015年-2019年应用TAVR术和SAVR治疗AS的病例资料,对使用TAVR和SAVR两组患者根据人口学以及病情的基线特征进行匹配,对比分析两组患者住院期间发生的住院总费用、费用结构和人均住院天数。结果:共收集285例(TAVR 92例,SAVR 193例)患者资料,PSM匹配后共获得TAVR和SAVR各30例。AS患者首次进行TAVR术或SAVR术的平均住院总费用分别为284476元和153772元,其中材料费用占比分别为90.2%和57.2%,住院总费用和材料费用两组之间都具有显著统计学差异。住院天数方面,TAVR术、SAVR术分别是9.3天和15.0天,具有统计学差异。结论:TAVR术对比SAVR术治疗主动脉瓣狭窄可以显著降低住院天数,然而TAVR术的住院总费用显著高于SAVR术,患者经济负担较重,临床应用与推广TAVR术时应当给予关注。

Abstract

Objective: To assess the in-hospital costs of transcatheter aortic valve replacement (TAVR) vs. surgical aortic valve replacement (SAVR) in the treatment of severe aortic stenosis. Methods: Patients treated with TAVR and SAVR in Shanghai Zhongshan Hospital from 2015 to 2019 were retrospectively collected, according to demography and baseline characteristics of the disease, propensity score matching (PSM) was used to control for baseline bias factors. The total hospitalization expenses, cost structure and per capita hospitalization days of the two groups were compared and analyzed. Results: A total of 285 cases (92 cases of TAVR and 193 cases of SAVR) were collected. After PSM, 30 cases of TAVR and 30 cases of SAVR were obtained. The results showed that the average total hospitalization cost of AS patients undergoing TAVR or SAVR for the first time was 284,476 yuan and 153,772 yuan, respectively, of which consumables cost accounted for 90.2% and 57.2%, respectively. The total hospitalization cost and consumables cost showed statistical differences between the two groups. In terms of hospitalization days, TAVR and SAVR were 9.3 and 15.0 days, respectively, with statistical differences. Conclusion: Compared with SAVR, TAVR can significantly reduce the length of hospital stay in the treatment of severe aortic stenosis. However, the total in-hospital costs of TAVR is significantly higher than SAVR, which leads to a heavy economic burden. Thus, we should pay attention to the clinical application and promotion of TAVR.

关键词

经导管主动脉瓣置换术 / 外科主动脉瓣置换术 / 住院费用

Key words

Transcatheter aortic valve replacement / Surgical aortic valve replacement / in-hospital costs

引用本文

导出引用
孙辉, 侯士强, 金春林, 潘文志, 周达新, 王海银. TAVR术对比SAVR术治疗重度AS的住院费用分析——基于真实世界数据[J]. 中国医疗保险. 2022, 0(1): 70-74 https://doi.org/10.19546/j.issn.1674-3830.2022.1.013
Sun Hui, Hou Shiqiang, Jin Chunlin, Pan Wenzhi, Zhou Daxin, Wang Haiyin. In-hospital Costs Analysis of Transcatheter Versus Surgical Aortic Valve Replacement in the Treatment of Severe Aortic Stenosis——Based on Real World Data[J]. China Health Insurance. 2022, 0(1): 70-74 https://doi.org/10.19546/j.issn.1674-3830.2022.1.013
中图分类号: F840.684 C913.7   

参考文献

[1] Michail M, Davies JE, Cameron JD, et al.Pathophysiological coronary and microcirculatory flow alterations in aortic stenosis[J]. Nat Rev Cardiol, 2018, 15(7): 420-431.
[2] Thaden JJ, Nkomo VT, Enriquez-Sarano M.The global burden of aortic stenosis. Prog Cardiovasc Dis. 2014,56(6):565-571.
[3] 颜秋文,邵国丰.经导管主动脉瓣置换术在主动脉瓣狭窄治疗中的新进展[J].浙江医学,2020,42(23):2594-2598.
[4] Cribier A, Eltchaninoff H, Bash A, et al.Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis:first human case description. Circulation,2002,106(24): 3006-3008.
[5] 葛均波, 周达新, 潘文志等. 经皮主动脉瓣置入术一例报道附操作要点. 中国介入心脏病杂志,2010,18(5):243-246.
[6] 刘展,潘莹丽,涂朝凤等.基于倾向得分的伪权数构造与混合样本推断[J].统计与决策,2021,37(02):20-24.
[7] 周达新,潘文志,吴永健等.经导管主动脉瓣置换术中国专家共识(2020更新版)[J].中国介入心脏病学杂志,2020,28(06):301-309.
[8] 潘文志,龙愉良,周达新等.2020年经导管瓣膜治疗主要进展[J].中国胸心血管外科临床杂志,2021,28(04):371-375.
[9] Osnabrugge RL, Head SJ, Genders TS, et al.Costs of transcatheter versus surgical aortic valve replacement in intermediate-risk patients. Ann Thorac Surg. 2012,94(6):1954-60.
[10] Onohara T, Yoshikawa Y, Watanabe T, et al. Cost analysis of transcatheter versus surgical aortic valve replacement in octogenarians: analysis from a single Japanese center. Heart Vessels.2021 Mar 12.
[11] 陈英耀,刘文彬,唐檬等.我国卫生技术评估与决策转化研究概述[J].中国卫生政策研究, 2013,6(7):1-6.
[12] 明坚, 魏艳, 何运臻等. 医疗器械和诊断产品的卫生技术评估路在何方——基于国际经验的启示[J].中国医疗保险,2021(06):69-74.
[13] 国家医疗保障局,关于《基本医疗保险医用耗材支付管理暂行办法(征求意见稿)》 《医保医用耗材“医保通用名”命名规范(征求意见稿)》 公开征求意见的公告,[EB/OL].(2021-11-19) (2021-11-23) http://www.nhsa.gov.cn/art/2021/11/19/art_113_7352.html.
[14] 国家药品监督管理局,关于发布真实世界数据用于医疗器械临床评价技术指导原则(试行)的通告[EB/OL].(2020-11-16) (2021-12-10) https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20201126090030150.html.

Accesses

Citation

Detail

段落导航
相关文章

/